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Dear Sir 
In our recent UK consensus statement on the management of people with type 2 diabetes, we 
highlighted the top line results of the ‘Researching CV Events with a Weekly INcretin in Diabetes’ 
(REWIND) trial, which had been made available via a press release in November 2018 [1]. These data 
were subsequently presented at the 79th Scientific Sessions of the American Diabetes Association in 
June 2019 and simultaneously published in the Lancet [2,3]. Although REWIND has yet to be 
incorporated into national guidelines, we felt it important to highlight these new data and set them 
into the context of our consensus view. 
The REWIND trial recruited 9,901 people with type 2 diabetes, who had an HbA1c less than 9.5% 
(90mmol/mol) and an estimated glomerular filtration rate > 15mL/min. The mean age at recruitment 
was 66 years, 45% were female and 69% did not have known cardiovascular disease. Participants 
received the GLP-1 receptor agonist (GLP-1RA) dulaglutide 1.5mg once weekly or placebo on top of 
standard of care and the primary end-point was a composite of cardiovascular death, non-fatal 
myocardial infarction (MI) or non-fatal stroke. The primary endpoint was reported in 12% of subjects 
randomised to receive dulaglutide and 13% of the placebo group, giving a hazard ratio of 0.88 with 
confidence intervals (CI) between 0.79 and 0.99. Hence, statistically significant superiority of 
dulaglutide over placebo was demonstrated (P=0.026). For this reason, we would recommend that 
dulaglutide could be considered as one of the second-line therapies for people with type 2 diabetes 
and established or at very high risk of cardiovascular disease. 
The REWIND trial had the longest median duration of follow-up and a lower placebo event rate than 
any of the modern era of diabetes cardiovascular outcomes trials. This reflects the entry criteria which 
led to only 31% of participants having prior cardiovascular disease (defined as previous MI, ischaemic 
stroke, revascularisation, unstable angina with ECG changes or myocardial ischaemia on imaging or 
stress test). It is of particular note that the reduction in hazard ratio (0.87, CI 0.74-1.02) was the same 
in the primary prevention cohort as in those subjects with previous cardiovascular events, showing 
that the overall result was not driven by benefits in the high-risk subjects. This is in contrast to the 
cardiovascular outcomes seen with SGLT2-inhibitors, where it appears that benefit is only seen in type 
2 diabetes subjects with pre-existing atherosclerotic cardiovascular disease [4]. 
The beneficial impact of dulaglutide on the primary composite cardiovascular endpoint, irrespective 
of baseline cardiovascular risk, is worthy of discussion since LEADER, the first cardiovascular endpoint 
trial to demonstrate superiority of a GLP-1RA appeared to show little benefit in lower risk patients [5]. 
This outcome was supported by subsequent post hoc analyses of LEADER, which defined 
cardiovascular risk using alternative definitions to the trial inclusion criteria [6,7]. However, in a post 
hoc analysis of the SUSTAIN 6 cardiovascular outcome trial which examined once-weekly semaglutide 
versus placebo, there was no significance difference in the improved hazard ratio according to the 
baseline cardiovascular status (prior MI or stroke versus none; established disease versus risk factors 
only)[8]. The latter study urged caution due to the low numbers of events (in a trial lasting a median 
of only 2.1 Years) but it is supported by a recent meta-analysis of all currently published GLP-1RA 
cardiovascular outcomes trials [9]. In that publication, there was a reduction of cardiovascular events 
in people with type 2 diabetes both with and without a history of cardiovascular disease, and with lack 
of statistically significant interaction. The reduction in the hazard ratio for the lower risk cohort was, 
however, lower (0.94 versus 0.86) and the CI crossed the line of unity (0.83-1.07) perhaps consistent 
with a smaller benefit overall.  
Whilst REWIND potentially supports the earlier use of GLP-1RAs for primary prevention of 
cardiovascular disease in people with type 2 diabetes, we believe that it is too early to recommend 
this as a routine intervention and more data are needed. This view is consistent with guidelines 
recently updated by the European Society of Cardiology (ESC)[10]. Furthermore, although the relative 
risk reductions seen in REWIND were the same irrespective of baseline cardiovascular status, the 
absolute risk reduction was much lower in the lower risk subjects and this will clearly impact on cost-
effectiveness analyses when these are eventually performed. 
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